PRESS RELEASE published on 10/09/2025 at 13:30, 5 months 25 days ago Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells Telomir Pharmaceuticals announces new findings showing Telomir-1's impact on aggressive breast cancer cells, targeting iron-dependent regulation and cellular energy pathways Telomir-1 Telomir Pharmaceuticals Breast Cancer Cells Iron-dependent Regulation Cellular Energy Pathways
BRIEF published on 10/07/2025 at 13:35, 5 months 27 days ago Telomir Pharmaceuticals dévoile des résultats précliniques prometteurs dans le traitement du cancer de la prostate Cancer De La Prostate Telomir-1 Telomir Pharmaceuticals Thérapie Épigénétique Suppresseurs De Tumeurs
BRIEF published on 10/07/2025 at 13:35, 5 months 27 days ago Telomir Pharmaceuticals Unveils Promising Preclinical Results in Prostate Cancer Therapy Prostate Cancer Telomir-1 Telomir Pharmaceuticals Epigenetic Therapy Tumor Suppressors
PRESS RELEASE published on 10/07/2025 at 13:30, 5 months 27 days ago Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance Telomir Pharmaceuticals unveils new preclinical findings showing Telomir-1 reactivates tumor suppressor genes MASPIN and RASSF1A in aggressive prostate cancer models, offering potential for improved chemotherapy response and metastasis control Prostate Cancer Telomir-1 Telomir Pharmaceuticals Preclinical Findings Tumor Suppressor Genes
BRIEF published on 09/18/2025 at 14:05, 6 months 15 days ago Telomir-1 Shows Expanded Targeting of Histone Demethylases Telomir-1 Telomir Pharmaceuticals Epigenetic Therapy Histone Demethylases Cancer And Aging
BRIEF published on 09/18/2025 at 14:05, 6 months 15 days ago Telomir-1 montre un ciblage élargi des déméthylases d'histones Telomir-1 Telomir Pharmaceuticals Thérapie Épigénétique Histone Demethylases Cancer Et Vieillissement
PRESS RELEASE published on 09/18/2025 at 14:00, 6 months 15 days ago Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies Telomir Pharmaceuticals announces Telomir-1's new in vitro results inhibiting KDM5 family, expanding epigenetic therapy possibilities in cancer treatment and aging slowdown Telomir-1 Telomir Pharmaceuticals Epigenetic Therapy KDM5 Family Inhibition Cancer Aging Treatment
BRIEF published on 09/09/2025 at 14:05, 6 months 24 days ago Telomir Pharmaceuticals Unveils Promising Preclinical Cancer Data Cancer Research Telomir-1 Telomir Pharmaceuticals DNA Methylation CDKN2A
BRIEF published on 09/09/2025 at 14:05, 6 months 24 days ago Telomir Pharmaceuticals dévoile des données précliniques prometteuses sur le cancer Telomir-1 Telomir Pharmaceuticals Recherche Sur Le Cancer Méthylation De L'ADN CDKN2A
PRESS RELEASE published on 09/09/2025 at 14:00, 6 months 24 days ago Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy Telomir Pharmaceuticals announces new preclinical findings showing Telomir-1's ability to reverse CDKN2A gene silencing by DNA methylation, potentially restoring cancer cell cycle control and immune surveillance Cancer Therapy Telomir Pharmaceuticals Preclinical Findings DNA Methylation CDKN2A Gene
Published on 04/02/2026 at 22:00, 1 day 2 hours ago Star Copper Announces Closing of Charity Flow-Through Unit Private Placement
Published on 04/02/2026 at 18:32, 1 day 6 hours ago Datavault AI CEO Nathaniel Bradley to Present DataValue(R), DataScore(R), and Information Data Exchange(R) Technologies at XRP Tokyo 2026
Published on 04/02/2026 at 15:00, 1 day 9 hours ago Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Published on 04/02/2026 at 14:40, 1 day 10 hours ago Northfield Capital Completes Acquisition Of Additional Interest In Juno Corp. And Announces Issuance Of Class B Multiple Voting Shares
Published on 04/02/2026 at 14:30, 1 day 10 hours ago Worksport Announces COR(TM) Portable Energy System Is Now Fully Certified, Including Key UL and CSA Approvals, for North American Retail and Commercial Distribution
Published on 04/03/2026 at 18:00, 6 hours 53 minutes ago IEVA GROUP: IMPLEMENTATION OF A LIQUIDITY AGREEMENT WITH CREDIT INDUSTRIEL ET COMMERCIAL
Published on 04/03/2026 at 18:00, 6 hours 53 minutes ago IEVA GROUP: MISE EN OEUVRE D’UN CONTRAT DE LIQUIDITE AVEC LE CREDIT INDUSTRIEL ET COMMERCIAL
Published on 04/03/2026 at 17:45, 7 hours 7 minutes ago Atbash Launches on Chromia to Enable Verifiable, User-Controlled AI Systems
Published on 04/03/2026 at 17:40, 7 hours 13 minutes ago BROADPEAK SA: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 01.04.26.
Published on 04/03/2026 at 17:05, 7 hours 47 minutes ago At WMF a new edition of AI Global Summit, an international reference point on Artificial Intelligence
Published on 04/03/2026 at 18:46, 6 hours 6 minutes ago Disclosure of Share Capital and Voting Rights as of March 31, 2026
Published on 04/03/2026 at 18:46, 6 hours 6 minutes ago Déclaration du nombre d’actions et droits de vote au 31 mars 2026
Published on 04/03/2026 at 18:01, 6 hours 51 minutes ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/03/2026 at 18:00, 6 hours 53 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/03/2026 at 18:00, 6 hours 53 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 mars 2026